Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characterization of a Distinct Rectal Mucosal Transcriptome among Transgender Women utilizing Cross-Sex Hormone Therapy

ABSTRACT: A comparison of rectal mucosal RNA transcriptome findings between transgender women using feminizing hormone therapy, men who have sex with men engaging in receptive anal intercourse, and males who had never engaged in anal intercourse demonstrates differential gene expression involving pathways critical for mucosal inflammation, suggesting the urgent need for further exploration into the immunologic effects of cross-sex hormone therapy in the rectal mucosa and the potential impact on HIV transmission risk at this site.

ORGANISM(S): Homo sapiens

PROVIDER: GSE141785 | GEO | 2023/03/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

Project description:Human immunodeficiency virus (HIV) disproportionately affects men who have sex with men (MSM) and transgender women (TGW). Safe and acceptable topical HIV prevention methods that target the rectum are needed. MTN-017 was a phase 2, 3-period, randomized sequence, open-label, expanded safety and acceptability crossover study comparing rectally applied reduced-glycerin (RG) 1% tenofovir (TFV) and oral emtricitabine/TFV disoproxil fumarate (FTC/TDF). In each 8-week study period participants were randomized to RG-TFV rectal gel daily, or RG-TFV rectal gel before and after receptive anal intercourse (RAI; or at least twice weekly in the event of no RAI), or daily oral FTC/TDF. MSM and TGW (n = 195) were enrolled from 8 sites in the United States, Thailand, Peru, and South Africa with mean age of 31.1 years (range 18-64). The clinical results were reported here https://www.ncbi.nlm.nih.gov/pubmed/27986684. For the gene expression study, rectal biopsies were obtained from a subset of participants (n = 36) in the United States (Pittsburgh) and Thailand (Bangkok). Biopsies were provided at baseline and after each study period.

2020-07-07 | GSE138723 | GEO

Homo sapiens

Project description:The rectal mucosal transcriptome of men who have sex with men (MSM) engaging in condomless receptive anal intercourse (CRAI) compared with men who have never engaged in anal intercourse (controls)

| PRJNA325377 | ENA

Characterization of a Distinct Rectal Mucosal Transcriptome among Transgender Women utilizing Cross-Sex Hormone Therapy

Project description:Characterization of a Distinct Rectal Mucosal Transcriptome among Transgender Women utilizing Cross-Sex Hormone Therapy

| PRJNA594726 | ENA

Longitudinal DNA methylation profiling of individuals at baseline and 6 and 12 months following Gender Affirming Hormone Therapy (GAHT)

Project description:In individuals where gender identity and sex assigned at birth are markedly and consistently incongruent, as in the case of transgender people, feminisation or masculinisation may be sought through gender affirming hormone therapy (GAHT). In this study we profiled genome-wide DNA methylation in transgender women and transgender men, before and during GAHT (6 months and 12 months into hormone treatment).

2022-02-17 | GSE176394 | GEO

Six months of gender affirming hormone treatment modifies the methylome in the transgender population

Project description:The main objective was to carry out a prospective global CpG (cytosine-phosphate-guanine) methylation analysis before vs. after six months of gender affirming hormone treatment (GAHT), in a transgender population vs. a cisgender population.

2021-05-03 | GSE173717 | GEO

Microbiome Transgender

Project description:The vaginal microbiome of transgender men receiving gender affirming hormonal therapy in comparison to cisgender woman

| PRJEB71387 | ENA

CBLL1 is hypomethylated and correlates with cortical thickness in transgender men before gender affirming hormone treatment

Project description:We measured whole-genome DNA methylation by the Illumina Infinium Human Methylation 850 array and reported its correlation with cortical thickness (CTh) in 22 transgender men (TM) experiencing GD versus 25 cisgender men (CM) and 28 cisgender women (CW). With respect to the methylation analysis, TM vs. CW showed significant differences in 35 CpGs, while 2,155 CpGs were found when TM vs. CM were compared. With respect to correlation analysis, TM showed differences in methylation of CBLL1 and DLG1 genes that correlated with global and left hemisphere CTh. Both genes were hypomethylated in TM compared to the cisgender groups. Early onset TM showed a positive correlation between CBLL1 and several cortical regions in the frontal (left caudal middle frontal), temporal (right inferior temporal, left fusiform) and parietal cortices (left supramarginal and right paracentral). This is the first study relating CBLL1 methylation with CTh in transgender persons and supports a neurodevelopmental hypothesis of gender identity

2023-11-03 | GSE237955 | GEO

RNA-seq of human Tregs from healthy cisgender and transgender individuals and patients with juvenile-onset systemic lupus erythematosus (JSLE)

Project description:Sexual dimorphisms, which vary depending on age group and pubertal status, have been described across both the innate and adaptive immune system. We explored the influence of sex hormones on Treg differential gene expression in the context of adolescent health (cisgender and transgender individuals) and autoimmunity (juvenile-onset SLE).

2022-09-01 | E-MTAB-11919 | biostudies-arrayexpress

CBLL1 is hypomethylated and correlates with cortical thickness in transgender men before gender affirming hormone treatment

Project description:CBLL1 is hypomethylated and correlates with cortical thickness in transgender men before gender affirming hormone treatment

| PRJNA997300 | ENA

The molecular consequences of androgen activity in the human breast (ATAC-seq data)

Project description:The mammary gland is a hormone responsive organ and has been extensively studied under the influences of estrogen and progesterone. However, the molecular implications of androgen exposure in the normal breast remain elusive and unexplored, partially due to a lack of relevant tissue to study the functional consequences of androgen action. Transgender men are born female but identify as male, and many choose to undergo gender-affirming androgen therapy, which elicits wide-ranging masculinizing effects that help align their physical characteristics and gender identity. Here we perform single cell resolution profiling of androgen treated breast tissue from transgender men at the transcriptome, chromatin, and spatial level to elucidate the regulatory action of androgen. We show male-biased androgen receptor gene targets are specifically upregulated in androgen receptor expressing cell types, and that other sex-relevant changes are also initiated in cells lacking androgen receptor expression, through paracrine signaling cascades. We observe a functionally and structurally altered epithelium, shifts in immune populations and directed reduction of capillary vasculature. Finally, we discover evidence of the metabolic impact of androgen and demonstrate how the treatment induces fat loss by specifically targeting adipocyte function. This work provides a comprehensive and mechanistic characterization of the mammary tissue responses to androgen activity at single-cell resolution.

2023-03-07 | GSE168837 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data